Kronos Bio, Inc.
Kronos Bio, Inc. (KRON) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · KRON · as of Jun 9, 2026
Key Statistics
Explore Kronos Bio, Inc. Data
kron stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 5 · Buy rate: 100.0%
The KRON analyst consensus is Buy, based on ratings from 5 Wall Street analysts over the past 3 months. The average 12-month price target is $1.63, representing +85.23% upside from the current price of $0.88.
Competitors & Peers
kron competitorsKRON
ACHL
ALVR
ARPO
BLUE
RENBStock Performance
Full HistoryAbout Kronos Bio, Inc.
Kronos Bio, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to the identification and advancement of innovative therapies for cancer. Its therapeutic strategy centers on mo…
what is kronos bio, inc. · kron stock overview · kronos bio, inc. company profile · who is kronos bio, inc. ceo · kron NASDAQ · kronos bio, inc. headquarters · kronos bio, inc. business segments
About Stock Overview & Key Data
Kronos Bio, Inc. (KRON) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Oct 9, 2020. As of the latest trading session, KRON stock price is $0.88, with a market capitalization of $53.7M. The stock has returned -29.60% over the past 12 months and -9.29% year-to-date.
According to 5 Wall Street analysts, the consensus rating for Kronos Bio, Inc. stock is Buy, with an average 12-month price target of $1.63. In fiscal year 2024, Kronos Bio, Inc. reported revenue of $9.8M and net income of -$86.1M. For detailed data — including Kronos Bio, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Kronos Bio, Inc. (KRON) stock price is $0.88. The stock is traded on NASDAQ under the ticker symbol KRON. The 52-week range is $0.65 – $1.46.